Navigation Links
FDA Approves Head Lice Treatment for Children and Adults
Date:1/18/2011

SILVER SPRING, Md., Jan. 18, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice infestation in patients ages 4 years and older.  

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Head lice are parasitic insects found on people's head, eyebrows, and eyelashes. They feed on human blood several times a day but are not known to cause disease. Head lice are spread mainly by direct head-to-head contact with a person who already has head lice.  Lice move by crawling and can easily travel from child to child because children play closely together and often in large groups.

"Natroba provides another option for the topical treatment of head lice infestations, which are especially prevalent in the pediatric population," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research. "Head lice is a common problem among school children in the United States."

Natroba is a topical drug product and should be applied only to the child's scalp or hair.  The product should be used exactly as prescribed by a health care professional.

The safety and effectiveness of Natroba Topical Suspension 0.9 %, has been established in two multicenter, randomized, active-controlled studies. A total of 552 subjects received a 10-minute treatment with Natroba. If live lice were seen a week later, a second treatment was applied. The proportion of subjects who were lice-free fourteen days after the final treatment of Natroba was approximately 86 percent compared to 44 percent of the control group.  

Common adverse events reported include redness or irritation of the eyes and skin.

Safety in pediatric patients below the age of 4 years has not been established. Although Natroba is not approved for use in children younger than 4 years, it is especially important not to use in infants because the product contains benzyl alcohol.   Benzyl alcohol has been associated with serious adverse reactions, including death, when applied topically to the skin of children younger than 6 months.  

Natroba is manufactured for ParaPRO LLC of Carmel, Ind.

For more information:

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
2. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
3. FDA Approves New Dosage Strength for INTELENCE®
4. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
5. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
6. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
7. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
8. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
9. FDA Approves New Treatment Option for Late-Stage Breast Cancer
10. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
11. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... Israel , May 4, 2017  DarioHealth Corp. ... mobile health and big data solutions, today announced that ... A&D Company, and STI Technologies Limited to lower diabetes ... immediately. Through STI,s innoviCares card, which is available throughout ... , DarioHealth customers will be eligible for additional savings ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... 2017 , ... Therachat , a smart guided journaling tool for improving ... current state of anxiety in support of National Mental Health Awareness Month. , The ... and benchmarked general anxiety levels as well as identified the top triggers, impact to ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... North America for the scientific development, healthcare training and clinical application of medical ... in becoming certified to perform medical thermal imaging services. , The first new ...
(Date:5/22/2017)... ... May 22, 2017 , ... Dr. Kiya ... patients with periodontal plastic surgery treatments, including crown lengthening and gum ... provides these esthetic and functional procedures to help patients improve their oral health, ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
(Date:5/22/2017)... ... ... Galena, Alaska, has a population of less than 500 people. But, the little, ... build a nuclear plant by the TOSHIBA Corporation. , In “The Galena Nuclear Project: ... journey to get power to his small town, off the electrical grid. , “We ...
Breaking Medicine News(10 mins):